Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-105603
Filing Date
2025-11-04
Accepted
2025-11-04 07:13:51
Documents
3
Period of Report
2025-11-04

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0263592-6k_lakeshore.htm 6-K 12264
2 PRESS RELEASE - LAKESHORE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT FOR GOING-P ea026359201ex99-1_lakeshore.htm EX-99.1 16135
3 AGREEMENT AND PLAN OF MERGER, DATED NOVEMBER 4, 2025, BY AND AMONG LAKESHORE BIO ea026359201ex99-2_lakeshore.htm EX-99.2 480146
  Complete submission text file 0001213900-25-105603.txt   509904
Mailing Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629
Business Address BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629 17327133678
LakeShore Biopharma Co., Ltd. (Filer) CIK: 0001946399 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: 6-K | Act: 34 | File No.: 001-41598 | Film No.: 251446434
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)